Home » USA Broker Ratings » Gilead Sciences – Consenus Indicates Potential 1.3% Upside

Gilead Sciences – Consenus Indicates Potential 1.3% Upside

Gilead Sciences found using ticker (GILD) now have 23 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 90 and 53 calculating the mean target price we have 74.91. Now with the previous closing price of 73.96 this is indicating there is a potential upside of 1.3%. The 50 day MA is 71.53 while the 200 day moving average is 66.69. The company has a market capitalisation of $88,025m. You can visit the company’s website by visiting: http://www.gilead.com

Gilead Sciences, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma and Zydelig, a kinase inhibitor. In addition, the company offers Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. Further, it provides its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Additionally, the company focuses to develop product for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. It markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences has collaboration agreements with The Rockefeller University; Novartis AG; Lyndra Therapeutics; Kyverna Therapeutics; Glympse Bio; Renown Institute; Goldfinch Bio; Insitro; Novo Nordisk A/S; Yuhan Corporation; Eisai Co., Ltd.; Galapagos NV; Carna Biosciences Inc.; Nurix Therapeutics; Humanigen; and Kiniksa Pharmaceuticals, Ltd. The company was founded in 1987 and is headquartered in Foster City, California.

Join us on our new LinkedIn page

Follow us on LinkedIn